Skip to main content
Account

Table 2 Logistic model for POD24 with baseline characteristics (all patients).

From: Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study

Variable

Modality

Model with imputation (OR (95% CI))

Age (years)

Continuous

1.041 (1.012–1.071)

Performance status

>1

2. 06 (1.2–3.5)

B symptoms

Yes

1.60 (1.2–2.2)

LDH/normal limit

Continuous

2.567 (1.94–3.39)

Leukocytes (G/L)

Continuous

1.004 (1.001–1.006)

Ki-67

>30%

2.41 (1.8–3.3)

Blastoid histology

Yes

3.13 (2.1–4.7)